BNP Paribas Call 75 BRM 17.01.202.../ DE000PE896E1 /
12/11/2024 08:43:03 | Chg.+0.003 | Bid22:00:28 | Ask22:00:28 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.004EUR | +300.00% | - Bid Size: - |
- Ask Size: - |
BRISTOL-MYERS SQUIBB... | 75.00 - | 17/01/2025 | Call |
GlobeNewswire
02/09
CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center
GlobeNewswire
30/08
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
28/08
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
22/08
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire
15/08
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
12/08
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
Newsfile Corp
12/08
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
08/08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
07/08
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...
GlobeNewswire
05/08
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
GlobeNewswire
01/08
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire
01/08
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
31/07
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...
GlobeNewswire
25/07
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
24/07
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
GlobeNewswire
20/07
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program